Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.69 |
| ▸ | KDR | P35968 | 5/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.65 |
| ▸ | RAF1 | P04049 | 6/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.62 |
| ▸ | FLT4 | P35916 | 4/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693652 | 0.89 | KDR (0.59) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL378510 | 0.89 | KDR (0.59) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL22552999 | 0.84 | KDR (0.52) | BRAFKDRRAF1FLT4FLT1 | |
| SCHEMBL1013892 | 0.83 | BRAF (0.87) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL1779737 | 0.82 | BRAF (1.00) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL15580119 | 0.80 | KDR (0.51) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL372681 | 0.79 | PDGFRB (0.62) | BRAFKDRMAPK14FLT4PDGFRB | |
| SCHEMBL31324666 | 0.79 | PDGFRB (0.62) | BRAFKDRMAPK14FLT4PDGFRB | |
| SCHEMBL29693548 | 0.79 | PDGFRB (0.62) | BRAFKDRMAPK14FLT4PDGFRB | |
| SCHEMBL22566434 | 0.79 | PDGFRA (0.56) | BRAFKDRMAPK14RAF1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | BRAF 13/4885KDR 5/4885MAPK14 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.